文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

残疾与非残疾人群阿片类使用障碍治疗质量比较

Quality of Opioid Use Disorder Treatment for Persons With and Without Disabling Conditions.
PubMed 文献 · JAMA Netw Open · 2023-03-01
一句话结论华盛顿州医疗补助计划数据显示,残疾阿片类使用障碍患者接受任何药物治疗的可能性比非残疾者低40%(AOR 0.60),发展性残疾者最低(AOR 0.50)。

这项基于华盛顿州医疗补助计划2016-2019年数据的病例对照研究纳入84 728名18-64岁阿片类使用障碍(OUD)参保人(159 591人年),其中15.5%(24 743人年)有身体、感觉、发展性或认知残疾。残疾者接受任何OUD药物(丁丙诺啡、美沙酮或纳曲酮)的可能性比非残疾者低40%(AOR 0.60;95%CI 0.58-0.61;P<.001),各残疾类型均如此,发展性残疾者最低(AOR 0.50;95%CI 0.46-0.55;P<.001)。在使用OUD药物者中,残疾者维持治疗6个月的可能性比非残疾者低13%(AOR 0.87;95%CI 0.82-0.93;P<.001)。作者认为这些差异无法用临床原因解释,反映治疗不公平,需通过政策与干预改善残疾人群OUD治疗可及性。

要点

  • 残疾OUD患者接受任何OUD药物(丁丙诺啡、美沙酮或纳曲酮)的可能性比非残疾者低40%(AOR 0.60;95%CI 0.58-0.61;P<.001)。
  • 各残疾类型均存在差异,发展性残疾者接受OUD药物的可能性最低(AOR 0.50;95%CI 0.46-0.55;P<.001)。
  • 在使用OUD药物的残疾患者中,维持治疗6个月的可能性比非残疾者低13%(AOR 0.87;95%CI 0.82-0.93;P<.001)。
  • 研究人群15.5%(24 743人年)有身体、感觉、发展性或认知残疾,提示急诊/ICU需关注该人群OUD治疗可及性。

适用人群与场景

  • 华盛顿州全额医疗补助计划参保人,年龄18-64岁,连续参保12个月,研究年份内有OUD且未参加Medicare。
  • 数据来自门诊、住院和寄宿治疗机构的医疗补助索赔,涵盖2016-2019年(使用)和2017-2018年(连续性)。

研究设计与关键结果

  • 研究类型:病例对照研究;样本量84 728名参保人(159 591人年);人群:华盛顿州医疗补助计划OUD患者;暴露:残疾状态(身体、感觉、发展性、认知);对照:无上述残疾者。
  • 残疾者接受任何OUD药物(丁丙诺啡、美沙酮或纳曲酮)的可能性比非残疾者低40%(AOR 0.60;95%CI 0.58-0.61;P<.001)。
  • 发展性残疾者接受OUD药物的可能性最低(AOR 0.50;95%CI 0.46-0.55;P<.001)。
  • 在使用OUD药物者中,残疾者维持治疗6个月的可能性比非残疾者低13%(AOR 0.87;95%CI 0.82-0.93;P<.001)。

证据类型、等级与局限

  • 证据类型:病例对照研究;局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为政策与干预对增加残疾人群OUD药物可及性至关重要,以减少其发病率和死亡率。
  • 作者提出的潜在解决方案包括加强《美国残疾人法案》的执行、劳动力最佳实践培训,以及解决污名化、可及性和住宿需求问题。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Adverse outcomes associated with opioid use disorder (OUD) are disproportionately high among people with disabilities (PWD) compared with those without disability. A gap remains in understanding the quality of OUD treatment for people with physical, sensory, cognitive, and developmental disabilities, specifically regarding medications for OUD (MOUD), a foundation of treatment.

OBJECTIVE: To examine the use and quality of OUD treatment in adults with diagnosed disabling conditions, compared with adults without these diagnoses.

DESIGN, SETTING, AND PARTICIPANTS: This case-control study used Washington State Medicaid data from 2016 to 2019 (for use) and 2017 to 2018 (for continuity). Data were obtained for outpatient, residential, and inpatient settings with Medicaid claims. Participants included Washington State full-benefit Medicaid enrollees aged 18 to 64 years, continuously eligible for 12 months, with OUD during the study years and not enrolled in Medicare. Data analysis was performed from January to September 2022.

EXPOSURES: Disability status, including physical (spinal cord injury or mobility impairment), sensory (visual or hearing impairments), developmental (intellectual or developmental disability or autism), and cognitive (traumatic brain injury) disabilities.

MAIN OUTCOMES AND MEASURES: The main outcomes were National Quality Forum-endorsed quality measures: (1) use of MOUD (buprenorphine, methadone, or naltrexone) during each study year and (2) 6-month continuity of treatment (for those taking MOUD).

RESULTS: A total of 84 728 Washington Medicaid enrollees had claims evidence of OUD, representing 159 591 person-years (84 762 person-years [53.1%] for female participants, 116 145 person-years [72.8%] for non-Hispanic White participants, and 100 970 person-years [63.3%] for participants aged 18-39 years); 15.5% of the population (24 743 person-years) had evidence of a physical, sensory, developmental, or cognitive disability. PWD were 40% less likely than those without a disability to receive any MOUD (adjusted odds ratio [AOR], 0.60; 95% CI, 0.58-0.61; P < .001). This was true for each disability type, with variations. Individuals with a developmental disability were least likely to use MOUD (AOR, 0.50; 95% CI, 0.46-0.55; P < .001). Of those using MOUD, PWD were 13% less likely than people without disability to continue MOUD for 6 months (adjusted OR, 0.87; 95% CI, 0.82-0.93; P < .001).

CONCLUSIONS AND RELEVANCE: In this case-control study of a Medicaid population, treatment differences were found between PWD and people without these disabilities; these differences cannot be explained clinically and highlight inequities in treatment. Policies and interventions to increase MOUD access are critical to reducing morbidity and mortality among PWD. Potential solutions include improved enforcement of the Americans with Disabilities Act, workforce best practice training, and addressing stigma, accessibility, and the need for accommodations to improve OUD treatment for PWD.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Thomas CP, Stewart MT, Ledingham E, et al. Quality of Opioid Use Disorder Treatment for Persons With and Without Disabling Conditions. JAMA Netw Open. 2023. PMID: 36884250. doi:10.1001/jamanetworkopen.2023.2052

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。